Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells (Q38787449)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 March 2016

Language	Label	Description	Also known as
English	Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells	scientific article published on 07 March 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

phase I clinical trial

0 references

author name string

Fengtao You

1

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Licui Jiang

2

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Bozhen Zhang

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Qiang Lu

4

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Qiao Zhou

5

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Xiaoyang Liao

6

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Hong Wu

7

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Kaiqi Du

8

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Youcai Zhu

9

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Huimin Meng

10

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Zhishu Gong

11

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Yunhui Zong

12

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Lei Huang

13

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Man Lu

14

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Jirong Tang

15

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Yafen Li

16

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Xiaochen Zhai

17

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Xiangling Wang

18

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Sisi Ye

19

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Dan Chen

20

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Lei Yuan

21

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Lin Qi

22

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Lin Yang

23

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

publication date

7 March 2016

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Science in China. Series C: Life Sciences

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

59

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

386-397

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

MUC1 as a target antigen for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Toxicity management for patients receiving novel T-cell engaging therapies.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

MUC1 immunotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

TRUCKs: the fourth generation of CARs

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumor-associated epitope on MUC1.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

The clinical significance of hypoxia in human cancers

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Structure and biology of a carcinoma-associated mucin, MUC1.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Identification of TIA-1+ and granzyme B+ cytotoxic T cells in lichen sclerosus et atrophicus

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

MUC1 immunotherapy is here to stay

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Chemotactic antiviral cytokines promote infectious apical entry of human adenovirus into polarized epithelial cells

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

CAR mechanics: driving T cells into the MUC of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Chimeric antigen receptor T cells for sustained remissions in leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Chimeric antigen receptor T-cell therapy for ALL.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Suppression, subversion and escape: the role of regulatory T cells in cancer progression

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

CD28z CARs and armored CARs

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Strategies used for MUC1 immunotherapy: preclinical studies

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Strategies used for MUC1 immunotherapy: human clinical studies

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

MUC1 and the immunobiology of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

The role of tumor-associated antigens in the biology and immunotherapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Chimeric antigen receptor modified T cell therapy for B cell malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5024-7

21 January 2018

Identifiers

10.1007/S11427-016-5024-7

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38787449&oldid=2202071631"